NeuroPace (NPCE) Financials

$15.85 -0.14 (-0.88%)

Closing price 04:00 PM Eastern

Extended Trading

$15.84 -0.01 (-0.06%)

As of 04:10 PM Eastern

Annual Income Statements for NeuroPace

This table shows NeuroPace's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-47	-33	-27
Consolidated Net Income / (Loss)	-47	-33	-27
Net Income / (Loss) Continuing Operations	-47	-33	-27
Total Pre-Tax Income	-47	-33	-27
Total Operating Income	-41	-27	-22
Total Gross Profit	32	48	59
Total Revenue	46	65	80
Operating Revenue	46	65	80
Total Cost of Revenue	13	17	21
Operating Cost of Revenue	13	17	21
Total Operating Expenses	73	75	81
Selling, General & Admin Expense	51	55	57
Research & Development Expense	22	21	24
Total Other Income / (Expense), net	-6.29	-5.78	-5.47
Interest Expense	7.53	8.52	8.80
Interest & Investment Income	1.58	3.05	3.02
Other Income / (Expense), net	-0.34	-0.32	0.30
Basic Earnings per Share	($1.91)	($1.27)	($0.93)
Weighted Average Basic Shares Outstanding	24.59M	25.85M	29.13M
Diluted Earnings per Share	($1.91)	($1.27)	($0.93)
Weighted Average Diluted Shares Outstanding	24.59M	25.85M	29.13M
Weighted Average Basic & Diluted Shares Outstanding	25.10M	28.34M	32.56M
Cash Dividends to Common per Share	-	$0.00	$0.00

This table shows NeuroPace's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-12	-11	-10	-9.12	-7.26	-6.20	-8.93	-7.51	-5.45	-5.25
Consolidated Net Income / (Loss)	-12	-11	-10	-9.12	-7.26	-6.20	-8.93	-7.51	-5.45	-5.25
Net Income / (Loss) Continuing Operations	-12	-11	-10	-9.12	-7.26	-6.20	-8.93	-7.51	-5.45	-5.25
Total Pre-Tax Income	-12	-11	-10	-9.12	-7.26	-6.20	-8.93	-7.51	-5.45	-5.25
Total Operating Income	-10	-9.86	-8.32	-7.85	-5.95	-5.05	-7.55	-6.23	-4.24	-3.65
Total Gross Profit	7.97	8.80	10	12	12	14	13	14	15	16
Total Revenue	11	13	14	17	16	18	18	19	21	21
Operating Revenue	11	13	14	17	16	18	18	19	21	21
Total Cost of Revenue	3.19	3.99	4.10	4.54	4.19	4.47	4.78	5.12	5.64	5.28
Operating Cost of Revenue	3.19	3.99	4.10	4.54	4.19	4.47	4.78	5.12	5.64	5.28
Total Operating Expenses	18	19	19	20	18	19	21	20	20	20
Selling, General & Admin Expense	13	14	13	14	13	13	15	14	14	14
Research & Development Expense	5.61	5.09	5.26	5.34	4.80	5.38	5.78	6.07	5.75	6.05
Total Other Income / (Expense), net	-1.59	-1.29	-2.06	-1.27	-1.31	-1.15	-1.38	-1.28	-1.21	-1.60
Interest Expense	1.91	1.94	1.97	2.13	2.19	2.24	2.26	2.17	2.18	2.19
Interest & Investment Income	0.42	0.80	0.73	0.73	0.77	0.82	0.83	0.76	0.75	0.68
Other Income / (Expense), net	-0.10	-0.15	-0.82	0.12	0.12	0.27	0.05	0.12	0.22	-0.09
Basic Earnings per Share	($0.48)	($0.44)	($0.41)	($0.36)	($0.28)	($0.22)	($0.32)	($0.26)	($0.19)	($0.16)
Weighted Average Basic Shares Outstanding	24.73M	24.59M	25.10M	25.47M	26.02M	25.85M	28.29M	28.85M	29.44M	29.13M
Diluted Earnings per Share	($0.48)	($0.44)	($0.41)	($0.36)	($0.28)	($0.22)	($0.32)	($0.26)	($0.19)	($0.16)
Weighted Average Diluted Shares Outstanding	24.73M	24.59M	25.10M	25.47M	26.02M	25.85M	28.29M	28.85M	29.44M	29.13M
Weighted Average Basic & Diluted Shares Outstanding	24.90M	25.10M	25.41M	25.86M	26.28M	28.34M	28.77M	29.20M	29.85M	32.56M

This table details how cash moves in and out of NeuroPace's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-13	11	-4.63
Net Cash From Operating Activities	-37	-20	-18
Net Cash From Continuing Operating Activities	-37	-20	-18
Net Income / (Loss) Continuing Operations	-47	-33	-27
Consolidated Net Income / (Loss)	-47	-33	-27
Depreciation Expense	0.27	0.17	0.21
Amortization Expense	2.98	1.72	1.79
Non-Cash Adjustments To Reconcile Net Income	12	12	13
Changes in Operating Assets and Liabilities, net	-4.79	-1.07	-5.45
Net Cash From Investing Activities	24	23	8.99
Net Cash From Continuing Investing Activities	24	23	8.99
Purchase of Property, Plant & Equipment	-0.60	-0.17	-0.31
Sale and/or Maturity of Investments	24	23	9.30
Net Cash From Financing Activities	0.49	8.13	4.33
Net Cash From Continuing Financing Activities	0.49	8.13	4.33
Repurchase of Common Equity	-0.35	-0.31	0.00
Issuance of Common Equity	0.90	8.69	5.21
Other Financing Activities, net	-0.06	-0.26	-0.88
Cash Interest Paid	4.46	4.48	6.23

This table details how cash moves in and out of NeuroPace's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-0.01	0.92	0.12	1.14	1.86	8.34	-5.06	-0.15	2.57	-1.99
Net Cash From Operating Activities	-6.98	-7.84	-9.70	-4.36	-2.30	-3.34	-7.53	-3.90	-1.72	-4.80
Net Cash From Continuing Operating Activities	-6.98	-7.84	-9.70	-4.36	-2.30	-3.34	-7.53	-3.90	-1.72	-4.80
Net Income / (Loss) Continuing Operations	-12	-11	-10	-9.12	-7.26	-6.20	-8.93	-7.51	-5.45	-5.25
Consolidated Net Income / (Loss)	-12	-11	-10	-9.12	-7.26	-6.20	-8.93	-7.51	-5.45	-5.25
Depreciation Expense	0.06	0.05	0.05	0.05	0.04	0.04	0.05	0.06	0.06	0.05
Amortization Expense	0.74	0.76	0.41	0.42	0.44	0.45	0.46	0.44	0.44	0.45
Non-Cash Adjustments To Reconcile Net Income	3.19	3.15	3.86	2.82	4.00	1.75	3.54	3.47	2.68	2.96
Changes in Operating Assets and Liabilities, net	0.82	-0.67	-3.64	1.47	0.48	0.62	-2.65	-0.35	0.55	-3.00
Net Cash From Investing Activities	6.97	8.90	10	5.30	4.19	3.47	2.40	3.24	1.40	1.96
Net Cash From Continuing Investing Activities	6.97	8.90	10	5.30	4.19	3.47	2.40	3.24	1.40	1.96
Purchase of Property, Plant & Equipment	-0.03	-0.10	-0.13	-	-0.01	-0.03	-0.10	-0.06	-0.10	-0.04
Sale and/or Maturity of Investments	7.00	9.00	10	5.30	4.20	3.50	2.50	3.30	1.50	2.00
Net Cash From Financing Activities	-0.01	-0.14	-0.26	0.20	-0.03	8.21	0.07	0.51	2.90	0.85
Net Cash From Continuing Financing Activities	-0.01	-0.14	-0.26	0.20	-0.03	8.21	0.07	0.51	2.90	0.85
Issuance of Common Equity	-	0.21	0.00	0.25	0.01	8.44	0.72	0.58	0.03	3.87
Other Financing Activities, net	-0.01	-0.00	-0.15	-0.04	-0.04	-0.04	-0.65	-0.07	2.86	-3.02
Cash Interest Paid	0.97	0.98	1.02	1.13	1.16	1.17	1.17	1.19	1.93	1.93

This table presents NeuroPace's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	114	108	95
Total Current Assets	98	93	81
Cash & Equivalents	6.61	18	13
Short-Term Investments	71	48	39
Accounts Receivable	7.48	12	13
Inventories, net	9.71	11	13
Prepaid Expenses	3.11	2.74	2.35
Plant, Property, & Equipment, net	1.06	1.00	1.05
Total Noncurrent Assets	15	14	12
Other Noncurrent Operating Assets	15	14	12
Total Liabilities & Shareholders' Equity	114	108	95
Total Liabilities	79	87	87
Total Current Liabilities	11	16	15
Accounts Payable	2.15	2.33	2.95
Accrued Expenses	7.41	11	9.79
Current Deferred Revenue	0.00	1.09	0.56
Other Current Liabilities	1.42	1.63	1.86
Total Noncurrent Liabilities	68	71	71
Long-Term Debt	53	57	60
Other Noncurrent Operating Liabilities	15	14	12
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	35	21	8.01
Total Preferred & Common Equity	35	21	8.01
Preferred Stock	0.00	0.00	0.00
Total Common Equity	35	21	8.01
Common Stock	507	524	539
Retained Earnings	-471	-504	-531

This table presents NeuroPace's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	120	106	102	99	99	94	96
Total Current Assets	104	90	87	84	84	80	83
Cash & Equivalents	5.69	6.72	7.86	9.72	13	13	15
Short-Term Investments	80	61	56	52	46	43	41
Accounts Receivable	7.88	9.19	11	11	12	11	12
Inventories, net	8.58	11	10	9.76	11	11	12
Prepaid Expenses	2.50	2.60	2.05	1.59	2.26	2.08	2.12
Plant, Property, & Equipment, net	0.89	1.02	0.98	0.95	1.05	1.00	1.04
Total Noncurrent Assets	15	15	15	14	14	13	13
Other Noncurrent Operating Assets	15	15	15	14	14	13	13
Total Liabilities & Shareholders' Equity	120	106	102	99	99	94	96
Total Liabilities	77	79	81	83	85	85	86
Total Current Liabilities	9.42	9.88	12	13	13	13	15
Accounts Payable	1.18	1.83	1.81	1.21	3.27	2.29	2.16
Accrued Expenses	7.55	6.58	8.18	10	7.29	7.75	10
Current Deferred Revenue	-	-	-	-	0.87	0.81	0.75
Other Current Liabilities	0.69	1.47	1.52	1.57	1.68	1.74	1.80
Total Noncurrent Liabilities	68	69	69	70	71	72	72
Long-Term Debt	52	54	55	56	58	59	59
Other Noncurrent Operating Liabilities	16	15	15	14	13	13	12
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	43	27	21	16	14	9.89	9.82
Total Preferred & Common Equity	43	27	21	16	14	9.89	9.82
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	43	27	21	16	14	9.89	9.82
Common Stock	504	509	512	514	527	530	536
Retained Earnings	-460	-481	-490	-498	-513	-520	-526

This table displays calculated financial ratios and metrics derived from NeuroPace's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	0.75%	43.72%	22.14%
EBITDA Growth	-32.68%	32.43%	24.34%
EBIT Growth	-41.26%	33.17%	22.27%
NOPAT Growth	-71.86%	33.39%	20.25%
Net Income Growth	-30.49%	30.00%	17.64%
EPS Growth	11.98%	33.51%	26.77%
Operating Cash Flow Growth	-50.01%	46.56%	8.89%
Free Cash Flow Firm Growth	-94.11%	35.97%	5.51%
Invested Capital Growth	32.38%	8.49%	32.54%
Revenue Q/Q Growth	4.10%	8.68%	4.52%
EBITDA Q/Q Growth	-0.84%	16.03%	5.20%
EBIT Q/Q Growth	-2.46%	15.96%	4.67%
NOPAT Q/Q Growth	-2.11%	15.03%	6.06%
Net Income Q/Q Growth	-0.97%	13.05%	3.38%
EPS Q/Q Growth	-106.39%	14.77%	6.06%
Operating Cash Flow Q/Q Growth	0.97%	18.60%	-8.83%
Free Cash Flow Firm Q/Q Growth	-3.72%	14.76%	-7.40%
Invested Capital Q/Q Growth	3.32%	2.29%	20.59%
Profitability Metrics	-	-	-
Gross Margin	71.38%	73.56%	73.94%
EBITDA Margin	-83.23%	-39.13%	-24.24%
Operating Margin	-89.62%	-41.54%	-27.12%
EBIT Margin	-90.36%	-42.02%	-26.74%
Profit (Net Income) Margin	-103.43%	-50.38%	-33.97%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	114.47%	119.89%	127.02%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-316.46%	-177.48%	-116.97%
ROIC Less NNEP Spread (ROIC-NNEP)	-275.40%	-95.51%	760.04%
Return on Net Nonoperating Assets (RNNOA)	229.50%	58.58%	-72.38%
Return on Equity (ROE)	-86.96%	-118.91%	-189.35%
Cash Return on Invested Capital (CROIC)	-344.33%	-185.63%	-144.96%
Operating Return on Assets (OROA)	-33.21%	-24.79%	-21.12%
Return on Assets (ROA)	-38.02%	-29.72%	-26.83%
Return on Common Equity (ROCE)	-86.96%	-118.91%	-189.35%
Return on Equity Simple (ROE_SIMPLE)	-135.38%	-159.56%	-338.71%
Net Operating Profit after Tax (NOPAT)	-29	-19	-15
NOPAT Margin	-62.73%	-29.08%	-18.98%
Net Nonoperating Expense Percent (NNEP)	-41.06%	-81.98%	-877.02%
Return On Investment Capital (ROIC_SIMPLE)	-	-24.51%	-22.46%
Cost of Revenue to Revenue	28.62%	26.44%	26.06%
SG&A Expenses to Revenue	112.79%	83.33%	71.46%
R&D to Revenue	48.21%	31.76%	29.60%
Operating Expenses to Revenue	161.00%	115.09%	101.06%
Earnings before Interest and Taxes (EBIT)	-41	-27	-21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-38	-26	-19
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.07	13.12	41.68
Price to Tangible Book Value (P/TBV)	1.07	13.12	41.68
Price to Revenue (P/Rev)	0.82	4.14	4.18
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.23	23.44	23.05
Enterprise Value to Revenue (EV/Rev)	0.28	4.00	4.26
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	1.52	2.76	7.43
Long-Term Debt to Equity	1.52	2.76	7.43
Financial Leverage	-0.83	-0.61	-0.10
Leverage Ratio	2.29	4.00	7.06
Compound Leverage Factor	2.62	4.80	8.96
Debt to Total Capital	60.34%	73.39%	88.14%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	60.34%	73.39%	88.14%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	39.66%	26.61%	11.86%
Debt to EBITDA	-1.40	-2.22	-3.07
Net Debt to EBITDA	0.65	0.37	-0.35
Long-Term Debt to EBITDA	-1.40	-2.22	-3.07
Debt to NOPAT	-1.85	-2.99	-3.92
Net Debt to NOPAT	0.86	0.50	-0.45
Long-Term Debt to NOPAT	-1.85	-2.99	-3.92
Altman Z-Score	-5.37	-4.07	-4.60
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	8.90	5.71	5.37
Quick Ratio	7.73	4.85	4.33
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-31	-20	-19
Operating Cash Flow to CapEx	-6,114.26%	-11,387.86%	-5,865.69%
Free Cash Flow to Firm to Interest Expense	-4.13	-2.34	-2.14
Operating Cash Flow to Interest Expense	-4.90	-2.31	-2.04
Operating Cash Flow Less CapEx to Interest Expense	-4.98	-2.33	-2.07
Efficiency Ratios	-	-	-
Asset Turnover	0.37	0.59	0.79
Accounts Receivable Turnover	6.25	6.61	6.35
Inventory Turnover	1.49	1.65	1.69
Fixed Asset Turnover	54.61	63.30	77.77
Accounts Payable Turnover	7.39	7.72	7.88
Days Sales Outstanding (DSO)	58.43	55.22	57.48
Days Inventory Outstanding (DIO)	245.64	220.76	215.58
Days Payable Outstanding (DPO)	49.38	47.25	46.33
Cash Conversion Cycle (CCC)	254.68	228.74	226.72
Capital & Investment Metrics	-	-	-
Invested Capital	10	11	15
Invested Capital Turnover	5.04	6.10	6.16
Increase / (Decrease) in Invested Capital	2.52	0.87	3.63
Enterprise Value (EV)	13	261	341
Market Capitalization	37	271	334
Book Value per Share	$1.40	$0.79	$0.27
Tangible Book Value per Share	$1.40	$0.79	$0.27
Total Capital	88	78	68
Total Debt	53	57	60
Total Long-Term Debt	53	57	60
Net Debt	-24	-9.50	6.77
Capital Expenditures (CapEx)	0.60	0.17	0.31
Debt-free, Cash-free Net Working Capital (DFCFNWC)	9.33	10	13
Debt-free Net Working Capital (DFNWC)	87	76	66
Net Working Capital (NWC)	87	76	66
Net Nonoperating Expense (NNE)	19	14	12
Net Nonoperating Obligations (NNO)	-24	-9.50	6.77
Total Depreciation and Amortization (D&A)	3.25	1.89	2.00
Debt-free, Cash-free Net Working Capital to Revenue	20.49%	15.34%	16.80%
Debt-free Net Working Capital to Revenue	190.55%	116.92%	82.83%
Net Working Capital to Revenue	190.55%	116.92%	82.83%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.91)	($1.27)	($0.93)
Adjusted Weighted Average Basic Shares Outstanding	24.59M	25.85M	29.13M
Adjusted Diluted Earnings per Share	($1.91)	($1.27)	($0.93)
Adjusted Weighted Average Diluted Shares Outstanding	24.59M	25.85M	29.13M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	25.10M	28.34M	32.56M
Normalized Net Operating Profit after Tax (NOPAT)	-29	-19	-15
Normalized NOPAT Margin	-62.73%	-29.08%	-18.98%
Pre Tax Income Margin	-103.43%	-50.38%	-33.97%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-5.46	-3.23	-2.43
NOPAT to Interest Expense	-3.79	-2.23	-1.72
EBIT Less CapEx to Interest Expense	-5.54	-3.25	-2.46
NOPAT Less CapEx to Interest Expense	-3.87	-2.25	-1.76
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.74%	-0.93%	0.00%

This table displays calculated financial ratios and metrics derived from NeuroPace's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	7.91%	16.30%	27.24%	61.86%	47.23%	40.84%	25.23%	16.63%	28.20%	19.18%
EBITDA Growth	-51.74%	-3.56%	3.01%	29.20%	43.54%	53.18%	19.41%	22.70%	34.25%	24.69%
EBIT Growth	-61.15%	-10.96%	6.44%	30.08%	43.36%	52.16%	17.97%	20.98%	31.04%	21.88%
NOPAT Growth	-63.37%	-9.36%	14.78%	28.43%	41.66%	48.77%	9.30%	20.68%	28.69%	27.68%
Net Income Growth	-45.80%	-4.24%	9.48%	28.10%	38.42%	44.37%	13.98%	17.65%	24.87%	15.32%
EPS Growth	-41.18%	-101.40%	12.77%	30.77%	41.67%	50.00%	21.95%	27.78%	32.14%	27.27%
Operating Cash Flow Growth	-57.66%	4.39%	14.88%	59.09%	67.00%	57.40%	22.38%	10.55%	25.11%	-43.58%
Free Cash Flow Firm Growth	25.95%	-65.15%	-8.95%	28.49%	43.94%	53.18%	49.13%	19.73%	15.49%	-40.32%
Invested Capital Growth	25.01%	32.38%	40.67%	8.69%	9.58%	8.49%	-2.18%	6.84%	12.43%	32.54%
Revenue Q/Q Growth	9.38%	14.63%	13.16%	14.08%	-0.50%	9.65%	0.62%	6.25%	9.37%	1.93%
EBITDA Q/Q Growth	7.36%	3.28%	5.55%	16.33%	26.13%	19.80%	-62.59%	19.75%	37.17%	8.14%
EBIT Q/Q Growth	6.85%	2.88%	8.69%	15.37%	24.53%	17.98%	-56.58%	18.47%	34.14%	7.08%
NOPAT Q/Q Growth	7.06%	3.33%	15.62%	5.59%	24.24%	15.11%	-49.38%	17.43%	31.89%	13.91%
Net Income Q/Q Growth	7.13%	5.42%	6.92%	12.06%	20.46%	14.57%	-43.95%	15.81%	27.44%	3.71%
EPS Q/Q Growth	7.69%	8.33%	6.82%	12.20%	22.22%	21.43%	-45.45%	18.75%	26.92%	15.79%
Operating Cash Flow Q/Q Growth	34.56%	-12.44%	-23.65%	55.04%	47.20%	-45.13%	-125.32%	48.19%	55.79%	-178.25%
Free Cash Flow Firm Q/Q Growth	-0.48%	-3.13%	-4.01%	33.66%	21.23%	13.86%	-13.02%	-4.69%	17.08%	-43.03%
Invested Capital Q/Q Growth	-13.54%	3.32%	33.59%	-8.92%	-12.83%	2.29%	20.45%	-0.53%	-8.27%	20.59%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	71.39%	68.83%	71.67%	72.51%	74.47%	75.20%	73.62%	73.40%	73.22%	75.41%
EBITDA Margin	-85.14%	-71.84%	-59.96%	-43.97%	-32.65%	-23.88%	-38.58%	-29.14%	-16.74%	-15.09%
Operating Margin	-91.41%	-77.09%	-57.48%	-47.57%	-36.22%	-28.04%	-41.63%	-32.35%	-20.15%	-17.02%
EBIT Margin	-92.34%	-78.23%	-63.13%	-46.83%	-35.52%	-26.57%	-41.35%	-31.73%	-19.11%	-17.42%
Profit (Net Income) Margin	-105.63%	-87.15%	-71.69%	-55.26%	-44.18%	-34.42%	-49.24%	-39.02%	-25.89%	-24.46%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	114.40%	111.40%	113.56%	118.00%	124.37%	129.54%	119.10%	122.98%	135.49%	140.41%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-312.45%	-272.22%	-166.52%	-152.31%	-146.37%	-119.82%	-148.17%	-125.73%	-93.10%	-73.40%
ROIC Less NNEP Spread (ROIC-NNEP)	-303.78%	-262.81%	-152.89%	-137.84%	-130.48%	-104.15%	-98.47%	-5.34%	71.10%	123.88%
Return on Net Nonoperating Assets (RNNOA)	260.30%	219.01%	113.11%	93.18%	84.96%	63.87%	34.52%	0.90%	-8.21%	-11.80%
Return on Equity (ROE)	-52.15%	-53.21%	-53.40%	-59.13%	-61.42%	-55.95%	-113.66%	-124.83%	-101.31%	-85.20%
Cash Return on Invested Capital (CROIC)	-334.50%	-344.33%	-268.26%	-219.52%	-223.84%	-185.63%	-133.84%	-140.67%	-151.13%	-144.96%
Operating Return on Assets (OROA)	-30.85%	-28.76%	-26.09%	-23.30%	-19.46%	-15.68%	-27.85%	-23.18%	-14.94%	-13.76%
Return on Assets (ROA)	-35.30%	-32.04%	-29.63%	-27.50%	-24.20%	-20.31%	-33.16%	-28.51%	-20.24%	-19.32%
Return on Common Equity (ROCE)	-52.15%	-53.21%	-53.40%	-59.13%	-61.42%	-55.95%	-113.66%	-124.83%	-101.31%	-85.20%
Return on Equity Simple (ROE_SIMPLE)	-107.42%	0.00%	-167.32%	-199.90%	-231.63%	0.00%	-219.69%	-302.44%	-285.97%	0.00%
Net Operating Profit after Tax (NOPAT)	-7.14	-6.90	-5.82	-5.50	-4.17	-3.54	-5.28	-4.36	-2.97	-2.56
NOPAT Margin	-63.99%	-53.96%	-40.24%	-33.30%	-25.35%	-19.63%	-29.14%	-22.65%	-14.10%	-11.91%
Net Nonoperating Expense Percent (NNEP)	-8.67%	-9.41%	-13.62%	-14.47%	-15.89%	-15.67%	-49.70%	-120.39%	-164.20%	-197.28%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-4.56%	-	-	-	-3.79%
Cost of Revenue to Revenue	28.61%	31.17%	28.33%	27.49%	25.53%	24.80%	26.38%	26.60%	26.78%	24.59%
SG&A Expenses to Revenue	112.51%	106.13%	92.79%	87.72%	81.50%	73.39%	83.34%	74.26%	66.04%	64.25%
R&D to Revenue	50.29%	39.79%	36.37%	32.36%	29.19%	29.85%	31.91%	31.50%	27.32%	28.18%
Operating Expenses to Revenue	162.80%	145.92%	129.15%	120.08%	110.69%	103.24%	115.25%	105.75%	93.37%	92.43%
Earnings before Interest and Taxes (EBIT)	-10	-10	-9.14	-7.73	-5.84	-4.79	-7.49	-6.11	-4.02	-3.74
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-9.50	-9.19	-8.68	-7.26	-5.36	-4.30	-6.99	-5.61	-3.53	-3.24
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.15	1.07	4.24	5.37	15.38	13.12	26.09	22.00	20.72	41.68
Price to Tangible Book Value (P/TBV)	2.15	1.07	4.24	5.37	15.38	13.12	26.09	22.00	20.72	41.68
Price to Revenue (P/Rev)	2.13	0.82	2.40	2.08	4.18	4.14	5.42	3.03	2.66	4.18
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	6.00	1.23	7.48	8.42	22.57	23.44	27.78	16.53	16.80	23.05
Enterprise Value to Revenue (EV/Rev)	1.37	0.28	2.11	1.92	4.09	4.00	5.40	3.08	2.69	4.26
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.20	1.52	1.96	2.58	3.42	2.76	4.05	5.97	6.03	7.43
Long-Term Debt to Equity	1.20	1.52	1.96	2.58	3.42	2.76	4.05	5.97	6.03	7.43
Financial Leverage	-0.86	-0.83	-0.74	-0.68	-0.65	-0.61	-0.35	-0.17	-0.12	-0.10
Leverage Ratio	2.09	2.29	2.60	2.98	3.68	4.00	4.90	6.32	7.47	7.06
Compound Leverage Factor	2.39	2.55	2.96	3.51	4.57	5.18	5.84	7.77	10.12	9.91
Debt to Total Capital	54.48%	60.34%	66.21%	72.10%	77.35%	73.39%	80.19%	85.65%	85.78%	88.14%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	54.48%	60.34%	66.21%	72.10%	77.35%	73.39%	80.19%	85.65%	85.78%	88.14%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	45.52%	39.66%	33.79%	27.90%	22.65%	26.61%	19.81%	14.35%	14.22%	11.86%
Debt to EBITDA	-1.38	-1.40	-1.43	-1.58	-1.83	-2.22	-2.43	-2.65	-2.90	-3.07
Net Debt to EBITDA	0.89	0.65	0.37	0.25	0.18	0.37	0.04	-0.16	-0.12	-0.35
Long-Term Debt to EBITDA	-1.38	-1.40	-1.43	-1.58	-1.83	-2.22	-2.43	-2.65	-2.90	-3.07
Debt to NOPAT	-1.86	-1.85	-1.96	-2.16	-2.50	-2.99	-3.14	-3.40	-3.67	-3.92
Net Debt to NOPAT	1.20	0.86	0.50	0.34	0.24	0.50	0.05	-0.20	-0.15	-0.45
Long-Term Debt to NOPAT	-1.86	-1.85	-1.96	-2.16	-2.50	-2.99	-3.14	-3.40	-3.67	-3.92
Altman Z-Score	-3.59	-4.47	-4.37	-4.70	-3.92	-3.37	-3.29	-4.77	-4.73	-3.99
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	11.08	8.90	9.13	7.52	6.55	5.71	6.43	6.37	5.59	5.37
Quick Ratio	9.91	7.73	7.78	6.47	5.67	4.85	5.38	5.31	4.63	4.33
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-9.13	-9.42	-9.79	-6.50	-5.12	-4.41	-4.98	-5.22	-4.33	-6.19
Operating Cash Flow to CapEx	-22,500.00%	-7,689.22%	-7,346.97%	0.00%	-25,577.78%	-10,440.63%	-7,238.46%	-6,190.48%	-1,724.00%	-12,300.00%
Free Cash Flow to Firm to Interest Expense	-4.79	-4.85	-4.98	-3.06	-2.34	-1.97	-2.21	-2.41	-1.98	-2.82
Operating Cash Flow to Interest Expense	-3.66	-4.04	-4.94	-2.05	-1.05	-1.49	-3.33	-1.80	-0.79	-2.19
Operating Cash Flow Less CapEx to Interest Expense	-3.68	-4.09	-5.00	-2.05	-1.05	-1.51	-3.38	-1.83	-0.84	-2.21
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.33	0.37	0.41	0.50	0.55	0.59	0.67	0.73	0.78	0.79
Accounts Receivable Turnover	6.04	6.25	5.33	5.68	6.29	6.61	6.63	6.49	6.69	6.35
Inventory Turnover	1.52	1.49	1.49	1.72	1.83	1.65	1.62	1.74	1.83	1.69
Fixed Asset Turnover	57.61	54.61	51.61	57.01	65.33	63.30	66.67	72.76	76.84	77.77
Accounts Payable Turnover	9.85	7.39	6.91	9.56	14.12	7.72	7.06	9.06	11.89	7.88
Days Sales Outstanding (DSO)	60.46	58.43	68.52	64.29	58.07	55.22	55.02	56.20	54.52	57.48
Days Inventory Outstanding (DIO)	240.19	245.64	245.55	212.70	199.02	220.76	224.99	210.15	199.22	215.58
Days Payable Outstanding (DPO)	37.06	49.38	52.84	38.19	25.85	47.25	51.74	40.28	30.71	46.33
Cash Conversion Cycle (CCC)	263.59	254.68	261.24	238.79	231.24	228.74	228.28	226.08	223.03	226.72
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	9.95	10	14	13	11	11	13	13	12	15
Invested Capital Turnover	4.88	5.04	4.14	4.57	5.77	6.10	5.08	5.55	6.60	6.16
Increase / (Decrease) in Invested Capital	1.99	2.52	3.97	1.00	0.95	0.87	-0.30	0.86	1.36	3.63
Enterprise Value (EV)	60	13	103	105	246	261	373	221	206	341
Market Capitalization	93	37	116	114	252	271	374	217	204	334
Book Value per Share	$1.75	$1.40	$1.10	$0.84	$0.63	$0.79	$0.51	$0.34	$0.34	$0.27
Tangible Book Value per Share	$1.75	$1.40	$1.10	$0.84	$0.63	$0.79	$0.51	$0.34	$0.34	$0.27
Total Capital	95	88	81	76	72	78	72	69	69	68
Total Debt	52	53	54	55	56	57	58	59	59	60
Total Long-Term Debt	52	53	54	55	56	57	58	59	59	60
Net Debt	-33	-24	-14	-8.72	-5.46	-9.50	-0.91	3.48	2.44	6.77
Capital Expenditures (CapEx)	0.03	0.10	0.13	0.00	0.01	0.03	0.10	0.06	0.10	0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)	9.54	9.33	13	11	9.81	10	12	12	11	13
Debt-free Net Working Capital (DFNWC)	95	87	80	75	71	76	71	68	68	66
Net Working Capital (NWC)	95	87	80	75	71	76	71	68	68	66
Net Nonoperating Expense (NNE)	4.65	4.24	4.55	3.63	3.09	2.66	3.64	3.15	2.48	2.69
Net Nonoperating Obligations (NNO)	-33	-24	-14	-8.72	-5.46	-9.50	-0.91	3.48	2.44	6.77
Total Depreciation and Amortization (D&A)	0.80	0.82	0.46	0.47	0.47	0.49	0.50	0.50	0.50	0.50
Debt-free, Cash-free Net Working Capital to Revenue	21.82%	20.49%	26.05%	20.81%	16.30%	15.34%	17.66%	16.85%	14.36%	16.80%
Debt-free Net Working Capital to Revenue	217.14%	190.55%	165.13%	136.55%	118.21%	116.92%	103.00%	94.18%	88.70%	82.83%
Net Working Capital to Revenue	217.14%	190.55%	165.13%	136.55%	118.21%	116.92%	103.00%	94.18%	88.70%	82.83%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.48)	($0.44)	($0.41)	($0.36)	($0.28)	($0.22)	($0.32)	($0.26)	($0.19)	($0.16)
Adjusted Weighted Average Basic Shares Outstanding	24.73M	24.59M	25.10M	25.47M	26.02M	25.85M	28.29M	28.85M	29.44M	29.13M
Adjusted Diluted Earnings per Share	($0.48)	($0.44)	($0.41)	($0.36)	($0.28)	($0.22)	($0.32)	($0.26)	($0.19)	($0.16)
Adjusted Weighted Average Diluted Shares Outstanding	24.73M	24.59M	25.10M	25.47M	26.02M	25.85M	28.29M	28.85M	29.44M	29.13M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	24.90M	25.10M	25.41M	25.86M	26.28M	28.34M	28.77M	29.20M	29.85M	32.56M
Normalized Net Operating Profit after Tax (NOPAT)	-7.14	-6.90	-5.82	-5.50	-4.17	-3.54	-5.28	-4.36	-2.97	-2.56
Normalized NOPAT Margin	-63.99%	-53.96%	-40.24%	-33.30%	-25.35%	-19.63%	-29.14%	-22.65%	-14.10%	-11.91%
Pre Tax Income Margin	-105.63%	-87.15%	-71.69%	-55.26%	-44.18%	-34.42%	-49.24%	-39.02%	-25.89%	-24.46%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-5.41	-5.15	-4.65	-3.64	-2.66	-2.14	-3.32	-2.82	-1.84	-1.71
NOPAT to Interest Expense	-3.75	-3.56	-2.96	-2.59	-1.90	-1.58	-2.34	-2.01	-1.36	-1.17
EBIT Less CapEx to Interest Expense	-5.42	-5.21	-4.72	-3.64	-2.67	-2.15	-3.36	-2.85	-1.89	-1.72
NOPAT Less CapEx to Interest Expense	-3.76	-3.61	-3.03	-2.59	-1.91	-1.60	-2.39	-2.04	-1.41	-1.18
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-0.74%	-0.99%	-1.10%	-1.23%	-0.93%	-0.62%	-0.62%	-0.66%	0.00%

Financials Breakdown Chart

Key Financial Trends

NeuroPace Inc (NPCE) quarterly results provide a view of a company with growing revenue but ongoing profitability and liquidity challenges. The following points summarize the key trends from the latest four quarters of 2024, with context from earlier periods included in the data you provided.

Revenue growth: Q4 2024 operating revenue was $21,466,000, up from $18,012,000 in Q4 2023, representing roughly 19% year‑over‑year growth.
Gross margin remained in the mid‑70s across 2024: gross profit around $16.19m on $21.47m in revenue (roughly 73–76% margin), with similar margins in Q3 and Q2/Q1 2024.
Financing cash inflows were positive in every 2024 quarter, providing ongoing liquidity: net cash from continuing financing activities ranged from about $72,000 to $2.9m per quarter.
Investing cash inflows were positive in multiple 2024 quarters, reflecting cash receipts from investments: net cash from continuing investing activities ranged from about $1.4m to $3.24m per quarter.
Operating income remained negative in all four quarters of 2024, signaling ongoing profitability challenges (Q4 -$3.65m, Q3 -$4.24m, Q2 -$6.23m, Q1 -$7.55m).
Debt load is elevated, with long‑term debt in the high $50m to $60m range and total liabilities around the mid‑$80m range in 2024, indicating substantial leverage relative to assets.
Retained earnings are deeply negative, reflecting a large accumulated deficit (roughly -$500m to -$525m across latest balance sheets).
Net cash from continuing operating activities was negative in all 2024 quarters, signaling ongoing cash burn from core operations (Q4 -$4.80m, Q3 -$1.72m, Q2 -$3.90m, Q1 -$7.53m).
Net income per share remained negative across 2024: Q4 -$0.16, Q3 -$0.19, Q2 -$0.26, Q1 -$0.32, with weighted‑average shares in the ~28.5–29.4 million range.
Total equity remains modest relative to liabilities, with about $9–14m in equity against roughly $84–86m in liabilities in 2024, signaling solvency risk and a weak balance sheet.

05/19/26 02:11 PM ETAI Generated. May Contain Errors.

NeuroPace Financials - Frequently Asked Questions

According to the most recent income statement we have on file, NeuroPace's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

NeuroPace's net income appears to be on a downward trend, with a most recent value of -$27.14 million in 2024, falling from -$47.08 million in 2022. The previous period was -$32.96 million in 2023. Check out NeuroPace's forecast to explore projected trends and price targets.

NeuroPace's total operating income in 2024 was -$21.67 million, based on the following breakdown:

Total Gross Profit: $59.09 million
Total Operating Expenses: $80.76 million

Over the last 2 years, NeuroPace's total revenue changed from $45.52 million in 2022 to $79.91 million in 2024, a change of 75.5%.

NeuroPace's total liabilities were at $86.63 million at the end of 2024, a 0.4% decrease from 2023, and a 9.2% increase since 2022.

In the past 2 years, NeuroPace's cash and equivalents has ranged from $6.61 million in 2022 to $18.06 million in 2023, and is currently $13.43 million as of their latest financial filing in 2024.

Over the last 2 years, NeuroPace's book value per share changed from 1.40 in 2022 to 0.27 in 2024, a change of -80.8%.

Related Companies

Financial statements for NASDAQ:NPCE last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroPace (NPCE) Financials

Financials Breakdown Chart

Key Financial Trends

NeuroPace Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroPace (NPCE) Financials

Annual Income Statements for NeuroPace

Quarterly Income Statements for NeuroPace

Annual Cash Flow Statements for NeuroPace

Quarterly Cash Flow Statements for NeuroPace

Annual Balance Sheets for NeuroPace

Quarterly Balance Sheets for NeuroPace

Annual Metrics And Ratios for NeuroPace

Quarterly Metrics And Ratios for NeuroPace

Financials Breakdown Chart

Key Financial Trends

NeuroPace Financials - Frequently Asked Questions

When does NeuroPace's financial year end?

How has NeuroPace's net income changed over the last 2 years?

What is NeuroPace's operating income?

How has NeuroPace's revenue changed over the last 2 years?

How much debt does NeuroPace have?

How much cash does NeuroPace have?

How has NeuroPace's book value per share changed over the last 2 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools